Catalysts · SNY · CIK 1121404 · page 3 of 3

SNY catalysts and FDA events, page 3.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on SNY PDUFA dates and upcoming catalysts. This page continues the list.

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
November 14, 2025tolebrutinib (SAR442168)SNYPrimary completionPrimary Progressive Multiple SclerosisCompletedClinicalTrials.gov
October 23, 2025sar444656 (kt-474) (SAR444656)SNYPrimary completionAtopic DermatitisWithdrawnClinicalTrials.gov
October 21, 2025bivv020 (sar445088) (BIVV020)SNYPrimary completionTransplant RejectionCompletedClinicalTrials.gov
October 9, 2025sar444656 (kt-474) (SAR444656)SNYPrimary completionHidradenitis SuppurativaWithdrawnClinicalTrials.gov
October 2, 2025Cerezyme (imiglucerase)SNYPrimary completionGaucher's Disease Type IIICompletedClinicalTrials.gov
October 1, 2025amlitelimab (SAR445229)SNYPrimary completionDermatitis AtopicCompletedClinicalTrials.gov
September 28, 2025tolebrutinib (SAR442168)SNYPDUFA date—DelayedSEC 8-K Exhibit 99.1
September 24, 2025amlitelimab (SAR445229)SNYPrimary completionAlopecia AreataWithdrawnClinicalTrials.gov
September 18, 2025rsvt vaccineSNYPrimary completionRSV ImmunizationWithdrawnClinicalTrials.gov
September 16, 2025itepekimab (sar440340) (REGN3500)SNYPrimary completionBronchiectasisCompletedClinicalTrials.gov
August 29, 2025Wayrilz (rilzabrutinib)SNYFDA approval—ApprovedFDA Novel Drug Approvals
August 29, 2025Wayrilz (rilzabrutinib)SNYPDUFA date—ApprovedSEC 8-K Exhibit 99.1
August 21, 2025amlitelimab (SAR445229)SNYPrimary completionDermatitis AtopicCompletedClinicalTrials.gov
August 6, 2025SAR447537SNYPrimary completionAlpha 1-Antitrypsin Deficiency; EmphysemaCompletedClinicalTrials.gov
July 23, 2025amlitelimab (SAR445229)SNYPrimary completionDermatitis AtopicCompletedClinicalTrials.gov
2H 2025Half-year discloseditepekimab (SAR440340)SNYTopline readoutCOPD in two phase 3 studies AERIFY-1ScheduledSEC 8-K Exhibit 99.1
June 30, 2025—SNYFDA approval—ApprovedSEC 8-K Exhibit 99.1
June 20, 2025—SNYPDUFA date—ScheduledSEC 8-K Exhibit 99.1
June 18, 2025SAR441566SNYPrimary completionRheumatoid ArthritisCompletedClinicalTrials.gov
June 11, 2025low dose (ld) rsvt vaccineSNYPrimary completionRSV Immunisation; Healthy VolunteersWithdrawnClinicalTrials.gov
June 11, 2025doxercalciferol (gz427397) (GZ427397)SNYPrimary completionSecondary Hyperparathyroidism-Chronic Kidney DiseaseWithdrawnClinicalTrials.gov
June 11, 2025Doxercalciferol (doxercalciferol)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
March 28, 2025Qfitlia™ (fitusiran)SNYFDA approvalTo prevent or reduce the frequency of bleeding episodes in hemophilia A or BPress ReleaseApprovedFDA Novel Drug Approvals
February 14, 2025Merilog (insulin aspart-szjj)SNYFDA approval—ApprovedopenFDA Drugs@FDA
October 25, 2024Sarclisa (isatuximab-irfc)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
September 20, 2024Sarclisa (isatuximab-irfc)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
Sep 2024Month disclosed—SNYFDA approval—ApprovedSEC 8-K Exhibit 99.1
June 10, 2024Kevzara (sarilumab)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
March 7, 2024Caprelsa (vandetanib)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
November 1, 2023Sarclisa (isatuximab-irfc)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
October 23, 2023Multaq (dronedarone hydrochloride)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
September 15, 2023Nexviazyme (avalglucosidase alfa-ngpt)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
May 2023Month disclosedAYVAKIT® (avapritinib)SNYFDA approvaladvanced SM in June 2021 and indolent SM in May 2023ApprovedSEC 8-K Exhibit 99.1
February 28, 2023Kevzara (sarilumab)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
August 31, 2022Xenpozyme (olipudase alfa-rpcp)SNYFDA approval—ApprovedFDA Novel Drug Approvals
July 18, 2022Clolar (clofarabine)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
August 6, 2021Nexviazyme (avalglucosidase alfa-ngpt)SNYFDA approval—ApprovedopenFDA Drugs@FDA
July 30, 2021Adlyxin (lixisenatide)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
July 16, 2021Fexinidazole (fexinidazole)SNYFDA approval—ApprovedopenFDA Drugs@FDA
April 30, 2021Aubagio (teriflunomide)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
March 31, 2021Sarclisa (isatuximab-irfc)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
March 11, 2021Fabrazyme (agalsidase beta)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
December 18, 2020Jevtana Kit (cabazitaxel)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
November 12, 2020Fexinidazole (fexinidazole)SNYComplete Response Letter—CRL issuedFDA Complete Response Letters
March 12, 2020Thyrogen (thyrotropin alfa)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
March 2, 2020Sarclisa (isatuximab-irfc)SNYFDA approval—ApprovedopenFDA Drugs@FDA
December 11, 2017Admelog (insulin lispro)SNYFDA approval—ApprovedopenFDA Drugs@FDA
May 22, 2017Kevzara (sarilumab)SNYFDA approval—ApprovedopenFDA Drugs@FDA
November 21, 2016Soliqua 100/33 (insulin glargine; lixisenatide)SNYFDA approval—ApprovedopenFDA Drugs@FDA
July 27, 2016Adlyxin (lixisenatide)SNYFDA approval—ApprovedopenFDA Drugs@FDA
Every catalyst is quoted from SNY’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.